PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced ...
Cancer
May 15, 2013 |
not rated yet |
0
Nearly 5 million asthmatics could benefit from antifungal therapy
An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from The University of Manchester and the University of Toronto.
Inflammatory disorders
May 08, 2013 |
not rated yet |
0
Study demonstrates that once-a-day pill offers relief from ragweed allergy symptoms
An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal ...
Immunology
May 07, 2013 |
not rated yet |
0
Pharmaceutical advances offer new options for health outcomes
Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.
Diseases, Conditions, Syndromes
May 20, 2013 |
not rated yet |
0
